Indaptus Therapeutics is trading at $3.05, up 7.02%, with no clear company-specific news explaining the September 30 pre-market gain. - The latest identified major news was a September 10 $24 million private placement, predating the move and not a confirmed catalyst. - On September 29, shares fell 13.37% to $2.85 in regular trading, then were reported up 8.07% after-hours at $3.08. - The mixed broad-market backdrop does not establish a market-wide explanation for the pre-market rise.